|
1
|
Lee JJ and Chu E: The adjuvant treatment
of stage III colon cancer: might less be more? Oncology (Williston
Park). 32:437–442, 444. 2018.PubMed/NCBI
|
|
2
|
Kang J, Chong SW, Park EJ, Baik SH and Lee
KY: Safety and feasibility of in-hospital early chemotherapy
initiation after surgery in patients with stage II–IV colon cancer.
Medicine (Baltimore). 98:e153712019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao J, Xue Y, Pan Y, Yao A, Wang G, Li D,
Wang T, Zhao S and Hou Y: Toll-like receptor 3 agonist poly I:C
reinforces the potency of cytotoxic chemotherapy via the
TLR3-UNC93B1-IFN-β signaling axis in paclitaxel-resistant colon
cancer. J Cell Physiol. 234:7051–7061. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun QL, Zhao CP, Wang TY, Hao XB, Wang XY,
Zhang X and Li YC: Expression profile analysis of long non-coding
RNA associated with vincristine resistance in colon cancer cells by
next-generation sequencing. Gene. 572:79–86. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gokduman K: Strategies targeting DNA
topoisomerase I in cancer chemotherapy: Camptothecins, nanocarriers
for camptothecins, organic non-camptothecin compounds and metal
complexes. Curr Drug Targets. 17:1928–1939. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoon SB and Park HR: Arctigenin inhibits
etoposide resistance in HT-29 colon cancer cells during
microenvironmental stress. J Microbiol Biotechnol. 29:571–576.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang J and Hu C: Evodiamine: A novel
anti-cancer alkaloid from Evodia rutaecarpa. Molecules.
14:1852–1859. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu H, Jin H, Gong W, Wang Z and Liang H:
Pharmacological actions of multi-target-directed evodiamine.
Molecules. 18:1826–1843. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guo Q, Liu Y, Zhao J and Wang J, Li Y,
Pang Y, Chen J and Wang J: Evodiamine inactivates NF-κB and
potentiates the antitumor effects of gemcitabine on tongue cancer
both in vitro and in vivo. Onco Targets Ther. 12:257–267. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang J, Chen ZH, Ren CM, Wang DX, Yuan
SX, Wu QX, Chen QZ, Zeng YH, Shao Y, Li Y, et al: Antiproliferation
effect of evodiamine in human colon cancer cells is associated with
IGF-1/HIF-1α downregulation. Oncol Rep. 34:3203–3211. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang C, Liu H, Gong XL, Wu LY and Wen B:
Effect of evodiamine and berberine on the interaction between DNMTs
and target microRNAs during malignant transformation of the colon
by TGF-β1. Oncol Rep. 37:1637–1645. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han S, Woo JK, Jung Y, Jeong D, Kang M,
Yoo YJ, Lee H, Oh SH, Ryu JH and Kim WY: Evodiamine selectively
targets cancer stem-like cells through the p53-p21-Rb pathway.
Biochem Biophys Res Commun. 469:1153–1158. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Russo A, Bazan V, Iacopetta B, Kerr D,
Soussi T and Gebbia N; TP53-CRC Collaborative Study Group, : The
TP53 colorectal cancer international collaborative study on the
prognostic and predictive significance of p53 mutation: Influence
of tumor site, type of mutation, and adjuvant treatment. J Clin
Oncol. 23:7518–7528. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jass JR: Pathogenesis of colorectal
cancer. Surg Clin North Am. 82:891–904. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ogino S, Lochhead P, Giovannucci E,
Meyerhardt JA, Fuchs CS and Chan AT: Discovery of colorectal cancer
PIK3CA mutation as potential predictive biomarker: Power and
promise of molecular pathological epidemiology. Oncogene.
33:2949–2955. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang D, Sun W, Zhou Y, Li P, Chen F, Chen
H, Xia D, Xu E, Lai M, Wu Y and Zhang H: Mutations of key driver
genes in colorectal cancer progression and metastasis. Cancer
Metastasis Rev. 37:173–187. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Urist MR: Bone: Formation by
autoinduction. Science. 150:893–899. 1965. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allaire JM, Roy SA, Ouellet C, Lemieux É,
Jones C, Paquet M, Boudreau F and Perreault N: Bmp signaling in
colonic mesenchyme regulates stromal microenvironment and protects
from polyposis initiation. Int J Cancer. 138:2700–2712. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Auclair BA, Benoit YD, Rivard N, Mishina Y
and Perreault N: Bone morphogenetic protein signaling is essential
for terminal differentiation of the intestinal secretory cell
lineage. Gastroenterology. 133:887–896. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bertrand FE, Angus CW, Partis WJ and
Sigounas G: Developmental pathways in colon cancer: Crosstalk
between WNT, BMP, Hedgehog and Notch. Cell cycle. 11:4344–4351.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan SX, Wang DX, Wu QX, Ren CM, Li Y,
Chen QZ, Zeng YH, Shao Y, Yang JQ, Bai Y, et al: BMP9/p38 MAPK is
essential for the antiproliferative effect of resveratrol on human
colon cancer. Oncol Rep. 35:939–947. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He BC, Gao JL, Zhang BQ, Luo Q, Shi Q, Kim
SH, Huang E, Gao Y, Yang K, Wagner ER, et al: Tetrandrine inhibits
Wnt/β-catenin signaling and suppresses tumor growth of human
colorectal cancer. Mol Pharmacol. 79:211–219. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo J, Deng ZL, Luo X, Tang N, Song WX,
Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al: A protocol
for rapid generation of recombinant adenoviruses using the AdEasy
system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ and
Wang PS: Anti-proliferative effects of evodiamine on human prostate
cancer cell lines DU145 and PC3. J Cell Biochem. 101:44–56. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Su T, Yang X, Deng JH, Huang QJ, Huang SC,
Zhang YM, Zheng HM, Wang Y, Lu LL and Liu ZQ: Evodiamine, a novel
NOTCH3 methylation stimulator, significantly suppresses lung
carcinogenesis in vitro and in vivo. Front Pharmacol. 9:4342018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Araújo Farias V, Carrillo-Gálvez AB,
Martin F and Anderson P: TGF-β and mesenchymal stromal cells in
regenerative medicine, autoimmunity and cancer. Cytokine Growth
Factor Rev. 43:25–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roy SAB, Allaire JM, Ouellet C,
Maloum-Rami F, Pomerleau V, Lemieux É, Babeu JP, Rousseau J, Paquet
M, Garde-Granger P, et al: Loss of mesenchymal bone morphogenetic
protein signaling leads to development of reactive stroma and
initiation of the gastric neoplastic cascade. Sci Rep. 6:327592016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Beppu H, Mwizerwa ON, Beppu Y, Dattwyler
MP, Lauwers GY, Bloch KD and Goldstein AM: Stromal inactivation of
BMPRII leads to colorectal epithelial overgrowth and polyp
formation. Oncogene. 27:1063–1070. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Means AL, Freeman TJ, Zhu J, Woodbury LG,
Marincola-Smith P, Wu C, Meyer AR, Weaver CJ, Padmanabhan C, An H,
et al: Epithelial Smad4 deletion Up-regulates inflammation and
promotes inflammation-associated cancer. Cell Mol Gastroenterol
Hepatol. 6:257–276. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Voorneveld PW, Reimers MS, Bastiaannet E,
Jacobs RJ, van Eijk R, Zanders MMJ, Herings RMC, van Herk-Sukel
MPP, Kodach LL, van Wezel T, et al: Statin use after diagnosis of
colon cancer and patient survival. Gastroenterology. 153:470–479
e4. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu RX, Ma Y, Hu XL, Ren WY, Liao YP, Wang
H, Zhu JH, Wu K, He BC and Sun WJ: Anticancer effects of oridonin
on colon cancer are mediated via BMP7/p38 MAPK/p53 signaling. Int J
Oncol. 53:2091–2101. 2018.PubMed/NCBI
|
|
34
|
Liu RX, Ren WY, Ma Y, Liao YP, Wang H, Zhu
JH, Jiang HT, Wu K, He BC and Sun WJ: BMP7 mediates the anticancer
effect of honokiol by upregulating p53 in HCT116 cells. Int J
Oncol. 51:907–917. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Luu HH, Song WX, Luo X, Manning D, Luo J,
Deng ZL, Sharff KA, Montag AG, Haydon RC and He TC: Distinct roles
of bone morphogenetic proteins in osteogenic differentiation of
mesenchymal stem cells. J Orthop Res. 25:665–677. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang HT, Ran CC, Liao YP, Zhu JH, Wang H,
Deng R, Nie M, He BC and Deng ZL: IGF-1 reverses the osteogenic
inhibitory effect of dexamethasone on BMP9-induced osteogenic
differentiation in mouse embryonic fibroblasts via PI3K/AKT/COX-2
pathway. J Steroid Biochem Mol Biol. 191:1053632019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhu JH, Liao YP, Li FS, Hu Y, Li Q, Ma Y,
Wang H, Zhou Y, He BC and Su YX: Wnt11 promotes BMP9-induced
osteogenic differentiation through BMPs/Smads and p38 MAPK in
mesenchymal stem cells. J Cell Biochem. 119:9462–9473. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mehrvarz Sarshekeh A, Advani S, Overman
MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E,
Manuel S, et al: Association of SMAD4 mutation with patient
demographics, tumor characteristics, and clinical outcomes in
colorectal cancer. PLoS One. 12:e01733452017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
François S, Eder V, Belmokhtar K, Machet
MC, Douay L, Gorin NC, Benderitter M and Chapel A: Synergistic
effect of human bone morphogenic protein-2 and mesenchymal stromal
cells on chronic wounds through hypoxia-inducible factor-1 α
induction. Sci Rep. 7:42722017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pugh CW, O'Rourke JF, Nagao M, Gleadle JM
and Ratcliffe PJ: Activation of hypoxia-inducible factor-1;
definition of regulatory domains within the alpha subunit. J Biol
Chem. 272:11205–11214. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Balamurugan K: HIF-1 at the crossroads of
hypoxia, inflammation, and cancer. Int J Cancer. 138:1058–1066.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lin MC, Lin JJ, Hsu CL, Juan HF, Lou PJ
and Huang MC: GATA3 interacts with and stabilizes HIF-1α to enhance
cancer cell invasiveness. Oncogene. 36:4243–4252. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Basu S and Murphy ME: Genetic modifiers of
the p53 pathway. Cold Spring Harb Perspect Med. 6:a0263022016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Molinari F and Frattini M: Functions and
regulation of the PTEN gene in colorectal cancer. Front Oncol.
3:3262014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xia M, Knezevic D, Tovar C, Huang B,
Heimbrook DC and Vassilev LT: Elevated MDM2 boosts the apoptotic
activity of p53-MDM2 binding inhibitors by facilitating MDMX
degradation. Cell Cycle. 7:1604–1612. 2008. View Article : Google Scholar : PubMed/NCBI
|
